The main danger of diabetes is its cardiovascular system complications, and hypertension can in turn exacerbate the cardiovascular system risk of abnormal glucose metabolism. In recent years, there is growing evidence of a close intrinsic link between diabetes and cardiovascular disease, and this link is manifested in two main ways. First, cardiovascular disease is the main destination of diabetes. On the other hand, patients with cardiovascular disease are a high-risk group for abnormal glucose metabolism. Therefore, the diabetic population should be the top priority in the prevention and treatment of hypertension. For diabetic patients, in addition to effective glycemic control, blood pressure control should be strengthened to minimize the risk of their cardiovascular system. A. Hypertension is an important risk factor for cardiovascular complications in diabetic patients Diabetes and hypertension are mutually high-risk groups. geiss et al. found that hypertension is an independent risk factor for macrovascular and microangiopathy in patients with type 2 diabetes. The UKPDS study also found that the risk of microangiopathy in diabetic patients increased with blood pressure levels and that diabetes-related mortality was strongly associated with blood pressure levels. The combined cardiovascular risk of diabetes and hypertension may be related to two factors: first, diabetic patients often have impaired autonomic function, resulting in reduced blood pressure autoregulation, which can lead to increased pressure in the microcirculatory vascular bed and consequently damage to the small arteries and capillary system of target organs; second, diabetic patients are more likely to have abnormal circadian rhythms of blood pressure, with reduced nocturnal blood pressure decreases and The abnormal blood pressure circadian rhythm is an independent risk factor for target organ damage. Active blood pressure control can significantly reduce the risk of cardiovascular endpoints in patients with diabetes Although increased blood pressure can increase the cardiovascular risk in patients with diabetes, active and effective antihypertensive therapy can significantly reduce this risk. Many studies have shown that antihypertensive therapy is as important as glucose therapy in patients with type 2 diabetes, and some have even found that the macrovascular benefit of aggressive and effective antihypertensive therapy in patients with diabetes is more significant than that of strict glycemic control. The UKPDS study showed that tight blood pressure control reduced diabetes-related mortality by 32%, reduced any diabetes-related endpoint events by 24%, and reduced strokes by 44%. The tight blood pressure control group had a 21% reduction in the risk of myocardial infarction, a 34% reduction in all macrovascular complications, and a 56% reduction in the risk of heart failure. For every 10 mmHg reduction in blood pressure, the risk of macrovascular and microvascular complications was reduced by 12-19% in diabetic patients. Controlling blood pressure below 140/90 mmHg in diabetic patients resulted in a significant reduction in cardiovascular endpoints, and the benefit was even greater when blood pressure was lowered to below 130/80 mmHg. In the HOT study, subjects were randomized to three groups with diastolic blood pressure targets of 90 mmHg, 85 mmHg, or less than 80 mmHg for 3.3-4.9 years of follow-up. A subgroup analysis of 1500 of these patients with diabetes found that the rate of cardiovascular events was 51% lower in patients with a diastolic target value of 80 mmHg or less than those with a diastolic target value of 90 mmHg or less. A post hoc analysis of subjects in the IDNT study also found that lowering systolic blood pressure to below 130 mmHg in patients with diabetic nephropathy resulted in a more significant reduction in the incidence of heart failure. The ABCD trial looked at the effect of tighter blood pressure control on the incidence of cardiovascular endpoints in patients with type II diabetes with normal blood pressure. The mean blood pressure at the end of the trial was 128/75 mmHg in the intensive care group and 137/81 mmHg in the usual care group, and the rate of cerebrovascular events was significantly lower in the former group than in the latter. These studies strongly suggest that controlling blood pressure at lower levels in diabetic patients helps to minimize the risk of macrovascular and microvascular endpoints. It is on the basis of this evidence that current hypertension guidelines recommend controlling blood pressure below 130/80 mmHg in patients with diabetes. This means that interventions should be made in diabetic patients while their blood pressure is still at high normal values. Third, take comprehensive measures to improve the blood pressure standard rate of diabetic patients Compared with the non-diabetic population, diabetic patients have a poorer response to antihypertensive drug therapy, coupled with the lower blood pressure target value (<130/80mmHg) in this population, so it is more difficult to achieve the standard. Epidemiological and clinical trials have confirmed that blood pressure compliance rates in the diabetic population are significantly lower than in the general hypertensive population. For example, in the ASCOT study, despite better monitoring and follow-up of antihypertensive medications, the BP compliance rate was significantly lower in diabetic patients (30%, target